Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock Series C	Preferred Stock Series D	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance, beginning at Dec. 31, 2019	$ 4	$ 2	$ 15,424	$ 12,456,989	$ (8,198,785)	$ 4,273,634
Balance, beginning (shares) at Dec. 31, 2019	3,501	2,000	15,424,394
Conversion of Series C Preferred Stock	$ (1)		$ 350	(349)
Conversion of Series C Preferred Stock (Shares)	(189)		350,000
Reversal of escrow shares related to Agribotix acquisition			$ (164)	164
Reversal of escrow shares related to Agribotix acquisition (Shares)			(164,375)
Accrued dividend on Series D Preferred Stock				(40,445)		(40,445)
Stock-based compensation expense				54,635		54,635
Stock-based compensation expense (Shares)
Net Loss					(403,273)	(443,718)
Balance, ending at Mar. 31, 2020	$ 3	$ 2	$ 15,610	12,470,994	(8,602,058)	3,884,551
Balance, ending (shares) at Mar. 31, 2020	3,312	2,000	15,610,019
Balance, beginning at Dec. 31, 2020			$ 58,636	47,241,757	(20,945,664)	26,354,729
Balance, beginning (shares) at Dec. 31, 2020			58,636,365
Sale of Common Stock, net of issuance costs			$ 1,057	6,312,886		6,313,943
Sale of Common Stock, net of issuance costs (Shares)			1,057,214
Sale of Common Stock from exercise of warrants			$ 2,517	8,302,851		8,305,368
Sale of Common Stock from exercise of warrants (Shares)			2,516,778
Exercise of options			$ 276	41,104		41,380
Exercise of options (Shares)			275,458
Stock-based compensation expense			$ 15	445,854		445,869
Stock-based compensation expense (Shares)			15,000
Net Loss					(2,930,530)	(2,930,530)
Balance, ending at Mar. 31, 2021			$ 62,501	$ 62,344,452	$ (23,876,194)	$ 38,530,759
Balance, ending (shares) at Mar. 31, 2021			62,500,815